Rusan Pharma, a leading Indian drugmaker specializing in narcotic and psychotropic products, has announced a substantial investment of ₹200 crore to bolster its manufacturing capabilities. The funds will be directed towards expanding tablet and injectable production at its Kandla Unit 1 facility in Gujarat, positioning the company to capitalize on India's burgeoning addiction treatment market.
Expanding Capacity for Addiction Care
The company estimates the addiction treatment market in India to reach ₹20,000-25,000 crore within the next three to four years. Dr. Navin Saxena, Founder Chairman of Rusan Pharma, highlighted the government's 'Nasha Mukt Bharat' (Drug-Free India) initiative as a significant driver for this growth. "The Government’s Nasha Mukt Bharat is a major initiative to address India’s growing addiction problem. It also presents a major growth opportunity for Rusan," Dr. Saxena stated.
Rusan Pharma has been active in addiction treatment since 1994, distributing products through government programs and a network of 240 private rehabilitation clinics. Despite these efforts, the company notes that treatment currently reaches only about 0.4% of drug patients seeking help. Rusan's product portfolio covers major addiction forms, including drugs, alcohol, and tobacco, with offerings like Addnok (buprenorphine) for drug addiction, naltrexone tablets and injectables for alcohol addiction, and nicotine transdermal patches for tobacco cessation.
The company projects its group business turnover to nearly double from its current ₹450 crore to ₹1,000 crore by the fiscal year 2027-28, driven by both addiction treatment and critical pain management segments.
Addressing Critical Pain Management and Global Reach
Critical pain management represents another key growth area for Rusan Pharma. The company operates in the narcotic and psychotropic segment, manufacturing essential pain relief medications such as fentanyl, morphine, buprenorphine, and nalbuphine, available in various forms including transdermal patches and long-acting injectables.
According to estimates cited by Rusan from leading oncologists, India faces a significant demand-supply gap for opioid-based painkillers, requiring 36 metric tons of morphine annually while current consumption hovers around 480 kg. Dr. Saxena attributed this disparity to the restrictive Narcotic Drugs and Psychotropic Substances (NDPS) Act and limited access to raw materials from government-controlled opium and alkaloid factories. He emphasized that access to essential pain medicines remains a critical concern, particularly in Tier-3 cities and rural areas, leading to terminal cancer patients enduring pain.
Internationally, Rusan Pharma has expanded its footprint, supplying APIs and finished dosage forms to markets including the UK, European Union, and the US. The company acquired a marketing firm in South Africa in 2024 and has forged out-licensing agreements in the EU, Russia, and Brazil, indicating a strong global expansion strategy. Rusan also invests a significant 10-12% of its group turnover in research and development, supporting its API and finished-dosage research center and a 104-bed clinical research facility.
While the stringent NDPS Act creates entry barriers that protect Rusan from low-cost competition, the company also cites regulatory and approval delays, both domestically and internationally, as constraints to faster market access and product launches.